Select a year:

4P-Pharma at BIO Europe Spring 2024

We look forward to attending BIOEuropeSpring, which will take place on March 18-20, 2024, in Barcelona. Our Business Development team, Roselina Lam and Daniel Sanchez Lopez, will represent us at this biopharma industry event. If you’re interested in learning more about our activities and pipeline or would like to schedule a meeting, please get in&hellip

Read More

HAPPY NEW YEAR 2024

The 4P-Pharma team sends you warm wishes for a fantastic year of 2024 filled with success, achievement, and unforgettable moments. We are thrilled to celebrate the first decade of our company foundation. Over the past ten years, we have faced challenges, deepened our understanding, and solved complex scientific questions. Each year has brought us joy,&hellip

Read More

4Moving Biotech forms its Scientific Advisory Board of World-Renowned Knee Osteoarthritis Experts

4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate’s phase 2b clinical trial.   “With their expertise in clinical study design and regulatory affairs, this high-level scientific advisory board will greatly contribute to the future success of 4P004, reinforcing our pioneering position in developing&hellip

Read More

4P-Pharma at Deeptech Connect

We look forward to seeing you on November 14, 2023 at the Carreau du Temple for the 2nd DeeptechConnect, in the HEALTH Village. An exceptional day dedicated to Deeptech, organized by the SATT Network. The first event to bring together industrialists and investors with startups stemming from French public research. For more information about our&hellip

Read More

4P-Pharma at BIO-Europe 2023

We are delighted to announce our upcoming BIO-Europe participation from November 6th to 8th in Munich!  Roselina Lam, our Business Development and Licensing-in Manager, is attending the event.   For more information about our pipeline or to schedule a meeting, contact us through our partnering platform: here

Read More

4Moving Biotech completes the recruitment of its Phase I clinical trial in patients with knee osteoarthritis

Our subsidiary, 4Moving Biotech, dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial. The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection&hellip

Read More